Metastatic castration-resistant prostate cancer
Enzalutamide, previously known as MDV300, is an oral, second-generation androgen receptor (AR) signaling inhibitor or antagonist that was approved by the Food and Drug Administration in 2012 for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) postdocetaxel. Preclinical studies...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , |
| Format: | article |
| Published: |
2013
|
| Online Access: | http://hdl.handle.net/10725/6242 http://dx.doi.org/10.4137/CMO.S11670 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813614/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|